From: A framework for assessing the consistency of drug classes across sources
DDI class | ATC class | MeSH class | Drugs common | Drugs only in ATC | Drugs only in MeSH | ES. | IS | Rel. |
---|---|---|---|---|---|---|---|---|
Triptans | Selective serotonin (5HT1) agonists | Tryptamines | 7 | 0 | 1 | 0.82 | -1 | Eq |
Proton pump inhibitors | Proton pump inhibitors | 2-Pyridinylmethylsulfinyl-benzimidazoles | 5 | 1 | 0 | 0.76 | 1 | Eq |
HMG CoA reductase inhibitors | HMG CoA reductase inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 0 | 2 | 0.76 | -1 | Eq |
Tricyclic antidepressants | Non-selective monoamine reuptake inhibitors | Antidepressive agents, Tricyclic | 10 | 2 | 2 | 0.69 | 0 | Eq |
Protease inhibitors | Protease inhibitors | HIV Protease inhibitors | 8 | 3 | 1 | 0.63 | 0.44 | Eq |
Narcotic analgesics | OPIOIDS | Narcotics | 15 | 3 | 11 | 0.50 | -0.48 | Eq |
Selective serotonin reuptake inhibitors (SSRIs) | Selective serotonin reuptake inhibitors | Serotonin uptake inhibitors | 6 | 0 | 8 | 0.40 | -1 | In |
MAO inhibitors | Monoamine oxidase inhibitors, non-selective | Monoamine oxidase inhibitors | 3 | 0 | 5 | 0.32 | -1 | In |
Macrolides | Macrolides | Macrolides | 8 | 0 | 21 | 0.26 | -1 | In |
Azoles | Imidazole and triazole derivatives | Azoles | 11 | 1 | 147 | 0.07 | -0.90 | In |
Amphetamine derivatives | - | - | Â | Â | Â | Â | Â | - |
Ergot alkaloids and derivatives | - | - | Â | Â | Â | Â | Â | - |
QT prolonging agents | - | - | Â | Â | Â | Â | Â | - |